Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

被引:8
作者
Villanueva, Fernando N.
Antonio Perez-Simon, Jose [1 ]
Silva, Fernando F.
Caballero-Velazquez, Teresa T.
Sanchez-Guijo, Fermin F.
Canizo, Conzuelo C.
Vazquez, Lourdes L.
Caballero, Dolores D.
San Miguel, Jesus F.
机构
[1] Hosp Clin Univ, Serv Hematol, Salamanca 37007, Spain
关键词
Gastrointestinal chronic graft-versus-hot disease; cGVHD; Beclomethasone dipropionate; BDP; Allogeneic stem cell transplantation; CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT; HEMATOPOIETIC-CELL TRANSPLANTATION; CLINICAL-TRIALS; MARROW TRANSPLANTATION; RANDOMIZED-TRIAL; PREDNISONE; DIAGNOSIS; SURVIVAL; LEUKEMIA;
D O I
10.1016/j.bbmt.2009.05.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most common approach for the treatment of chronic graft-versus-host disease (cGVHD) has been the long-term use of systemic steroids. Beclomethasone dipropionate (BDP) is a topically active corticosteroid with relatively low absorption from the gastrointestinal mucosa. It has been successfully used to treat acute GVHD (aGVHD), but its use in the cGVHD setting is far more limited. In the current study, BDP was administered to 33 patients who underwent allogeneic transplantation and had biopsy-proven gastrointestinal cGVHD (GI cGVHD). Twenty-six patients with GI cGVHD received BDP as first-line and 7 as either second-or third-line treatment. All patients received BDP together with a calcineurin inhibitor, except for I patient who was also receiving mycophenolate mofetil (MMF). BDP was administered for a minimum of 16 weeks and was tapered during 4 additional weeks. Of those patients receiving BDP as the first line of treatment, 22 (84.6%) achieved complete remission (CR) of GI cGVHD, 2 (7.7%) achieved a partial response (PR) and 2 (7.7%) did not respond or progressed. Median time to response was 28 days. Nevertheless, only 7 (27%) patients had maintained the response at last follow-up, whereas 19 (73%) finally relapsed or progressed. Median time to relapse was 147 days after the end of BDP. In the case of the patients who received BDP as a second-or third-line treatment, 3 (42.9%) achieved CR and 2 (28.6%) PR. For the whole series of patients, 13 patients (39.4%) were not receiving immunosuppressive treatment at final follow-up. Only 4 patients developed cytomegalovirus (CMV) reactivation, which was successfully treated with antiviral drugs. No fungal infection was observed during the treatment period. In conclusion, the current study shows that BDP, in the absence of systemic steroids, is a highly effective initial therapeutic approach for GI cGVHD, which helps to avoid complications related to systemic steroids.
引用
收藏
页码:1331 / 1336
页数:6
相关论文
共 50 条
  • [21] Histopathology of graft-versus-host disease
    Laenger, F.
    Puls, F.
    Buchholz, S.
    Loddenkemper, C.
    Ganser, A.
    Kreipe, H.
    [J]. PATHOLOGE, 2011, 32 (02): : 144 - 151
  • [22] Outcome of gastrointestinal graft-versus-host disease according to the treatment response
    Tamaki, Masaharu
    Nakasone, Hideki
    Misaki, Yukiko
    Yoshimura, Kazuki
    Gomyo, Ayumi
    Hayakawa, Jin
    Kusuda, Machiko
    Akahoshi, Yu
    Ishihara, Yuko
    Kawamura, Koji
    Tanihara, Aki
    Sato, Miki
    Terasako-Saito, Kiriko
    Kameda, Kazuaki
    Wada, Hidenori
    Kikuchi, Misato
    Kimura, Shun-ichi
    Kako, Shinichi
    Kanda, Yoshinobu
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (10) : 1951 - 1960
  • [23] Proteomic Analysis of Saliva from Patients with Oral Chronic Graft-Versus-Host Disease
    Devic, Ivana
    Shi, Min
    Schubert, Mark M.
    Lloid, Michele
    Izutsu, Kenneth T.
    Pan, Catherine
    Missaghi, Melody
    Morton, Thomas H.
    Mancl, Lloyd A.
    Zhang, Jing
    Presland, Richard B.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (07) : 1048 - 1055
  • [24] Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
    Martin, Paul J.
    Storer, Barry E.
    Rowley, Scott D.
    Flowers, Mary E. D.
    Lee, Stephanie J.
    Carpenter, Paul A.
    Wingard, John R.
    Shaughnessy, Paul J.
    DeVetten, Marcel P.
    Jagasia, Madan
    Fay, Joseph W.
    van Besien, Koen
    Gupta, Vikas
    Kitko, Carrie
    Johnston, Laura J.
    Maziarz, Richard T.
    Arora, Mukta
    Jacobson, Pamala A.
    Weisdorf, Daniel
    [J]. BLOOD, 2009, 113 (21) : 5074 - 5082
  • [25] Impact of chronic graft-versus-host disease on non-relapse mortality and survival
    Jiang, Justin
    Sigmund, Audrey M.
    Zhao, Qiuhong
    Elder, Patrick
    Vasu, Sumithira
    Jaglowski, Samantha
    Mims, Alice
    Choe, Hannah
    Larkin, Karilyn
    Wall, Sarah
    Grieselhuber, Nicole
    William, Basem
    Penza, Sam
    Benson, Don M.
    Efebera, Yvonne A.
    Sharma, Nidhi
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1698 - 1705
  • [26] Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease
    Davies, Lindsay C.
    Board-Davies, Emma
    Shamlou, Berfin
    Boberg, Erik
    Garming-Legert, Karin
    Le Blanc, Katarina
    [J]. CYTOTHERAPY, 2018, 20 (05) : 755 - 758
  • [27] Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies
    Nguyen, Joe T.
    Jessri, Maryam
    Costa-da-Silva, Ana C.
    Sharma, Rubina
    Mays, Jacqueline W.
    Treister, Nathaniel S.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [28] Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease
    Bojanic, Ines
    Stipetic, Marinka Mravak
    Pulanic, Drazen
    Desnica, Lana
    Mazic, Sanja
    Cepulic, Branka Golubic
    Seiwerth, Ranka Serventi
    Vrhovac, Radovan
    Nemet, Damir
    Pavletic, Steven Z.
    [J]. TRANSFUSION, 2018, 58 (06) : 1494 - 1499
  • [29] Treatment of chronic graft-versus-host disease in 2011
    Inamoto, Yoshihiro
    Flowers, Mary E. D.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2011, 18 (06) : 414 - 420
  • [30] Treatment of chronic graft-versus-host disease with bortezomib
    Pai, Chien-Chun Steven
    Chen, Mingyi
    Mirsoian, Annie
    Grossenbacher, Steven K.
    Tellez, Joseph
    Ames, Erik
    Sun, Kai
    Jagdeo, Jared
    Blazar, Bruce R.
    Murphy, William J.
    Abedi, Mehrdad
    [J]. BLOOD, 2014, 124 (10) : 1677 - 1688